Business Description
ContraFect Corp
NAICS : 325412
SIC : 2834
ISIN : US2123261024
Description
ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its DLA product candidate, exebacase, is currently being studied in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci, and the next product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumannii, and has demonstrated potent in vivo activity against these pathogens, even against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.
Financial Strength
| Name | Current | Vs Industry | Vs History |
|---|
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 14-Day RSI | 27.91 | |||||
| 6-1 Month Momentum % | -99.52 | |||||
| 12-1 Month Momentum % | -99.66 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History |
|---|
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | 0.09 | |||||
| EV-to-EBITDA | 0.1 | |||||
| Earnings Yield (Greenblatt) % | 1111.11 | |||||
| FCF Yield % | -23890100 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:CFRXQ
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ContraFect Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -19.27 | ||
| Beta | 14.53 | ||
| Volatility % | 130.37 | ||
| 14-Day RSI | 27.91 | ||
| 14-Day ATR ($) | 0.000007 | ||
| 20-Day SMA ($) | 0.0001 | ||
| 12-1 Month Momentum % | -99.66 | ||
| 52-Week Range ($) | 0.0001 - 0.04 | ||
| Shares Outstanding (Mil) | 10.7 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ContraFect Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ContraFect Corp Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
ContraFect Corp Frequently Asked Questions
What is ContraFect Corp(CFRXQ)'s stock price today?
The current price of CFRXQ is $0.00. The 52 week high of CFRXQ is $0.04 and 52 week low is $0.00.
When is next earnings date of ContraFect Corp(CFRXQ)?
The next earnings date of ContraFect Corp(CFRXQ) is 2024-12-30 Est..
Does ContraFect Corp(CFRXQ) pay dividends? If so, how much?
ContraFect Corp(CFRXQ) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers